Scheherazade Sadegh-Nasseri, M.Sc., Ph.D.
Ph.D. – University of California, Los Angeles, UCLA
Post-doc – Stanford University
Post-doc – NIH/NIAID
Division of Immunology, Department of Pathology
Johns Hopkins University School of Medicine
Ross Research Building, Room 664B
720 Rutland Ave., Baltimore, Md. 21205
Keywords: Molecular mechanisms in antigen processing and presentation, T cell memory survival, T cell activation, T cell tolerance, Host Immune responses to HIV
CD4+ helper T cells of the immune system recognize peptide fragments of self or foreign antigens that are loaded on MHC-II molecules. Understanding the biochemical and molecular factors that determine which peptides of a given antigen, called “immunodominant epitopes” are selected by the immune system for representing that particular antigen is critically important. Any alterations in the quality and quantity of MHC-II antigen presentation has major implications for the induction of immunologic memory, tolerance, and disease. In fact, it has now become clear that MHC-II antigen processing and presentation plays a major role in the pathophysiology of several autoimmune disorders including MS, infectious diseases such as HIV, and several cancers, including lung cancer.
Our lab has been defining the nature of MHC-II antigen processing and how this affects CD4+ T cell recognition and effector function. Among some of our past work, we have shown that having a peptide is essential for the MHC-II structure, determined the number and nature of peptide:MHC contacts to induce activation or hyporesponsiveness (anergy) in CD4+ T cells, and defined how a protein chaperone HLA-DM allows for selection of high-affinity peptides that can be stably presented to CD4+ T cells. Using the biochemical principles we elucidated from these early studies, we developed a reductionist cell-free MHC-II processing system that is able to identify immunodominant epitopes of a given protein antigen. This system has identified critical epitopes in proteins implicated in autoimmunity as well as protein antigens from influenza, malaria, and HIV-1.
During the past few years, we have been investigating the mechanism of another molecular chaperone, HLA-DO, in MHC-II antigen processing and its role in T cell selection and autoimmunity. Finally, we have recently began a foray into human immunology to investigate the purpose of inducible MHC-II expression on CD4+ T cells, a cell that normally is thought to exclusively respond to, but not present its own, peptides. With these studies, we aim to precisely define the critical molecular determinants of peptide antigen presentation on MHC-II molecules in both the murine and human immune systems. Our goal is ultimately to understand how alterations in peptide presentation and immunodominance can lead to human immune disease, and how to better develop vaccines for infections and cancer that promote T cell recognition of the correct antigenic epitopes.
Profile: Publications and Interests